Belvedere Trading
ABCL icon

Belvedere Trading’s AbCellera Biologics ABCL Stock Holding History

Belvedere Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$3.77K – 839
2023
Q1 		$3.77K Sell
500
-3,600
-88% -$32.7K ﹤0.01% 800
2022
Q4 		$41.5K Buy
+4,100
New +$47.4K ﹤0.01% 687

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Belvedere Trading's ABCL Position: Q1 2023 in Review

Belvedere Trading sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 1,861 shares — an estimated $16.9K sold.

Belvedere Trading first reported a position in ABCL in Q1 2022 and held it in 2 quarters. The position peaked at $172K in Q1 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Belvedere Trading reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 1,861 AbCellera Biologics shares in Q1 2023, an estimated $16.9K.
  • Belvedere Trading first reported a position in AbCellera Biologics in Q1 2022 and held it in 2 quarters.
  • Belvedere Trading's AbCellera Biologics position peaked at $172K in Q1 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.